The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Open accessAbstract
CONTEXT: Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders. OBJECTIVE: To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression. DESIGN: A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005. SETTING: Mood Disorders Research Unit at the National Institute of Mental Health. Patients Eighteen subjects with DSM-IV major depression (treatment resistant). INTERVENTIONS: After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion. Main Outcome Measure Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale. RESULTS: Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week. CONCLUSIONS: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Shortly thereafter, ketamine's robust antidepressant effects were confirmed in treatmentresistant depression (TRD) and bipolar disorder (BD) [5][6][7]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike traditional antidepressants, psychoplastogens produce both fast-acting and sustained beneficial behavioral effects after a single administration (Figure 1) (38–42).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, other NMDAR antagonists do not show antidepressant effects (Zarate et al., 2006)”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Zarate et al., 2006
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's half-life in the body is ;2 h (Autry et al., 2011), yet a single low-dose treatment elicits sustained (.1 week) antidepressant effects in patients (Berman et al., 2000;Zarate et al., 2006;Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Zarate et al., 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine alleviates depressive symptoms within hours in patients who have failed to respond to two or more conventional antidepressants, and the effects are sustained for 7 to 10 days.”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's anxiolytic effects have also been supported by placebo-controlled trials which demonstrated that the psychic anxiety item on the 21item HAM-D significantly improved after ketamine infusion (compared to saline); the psychic anxiety item was one of only four items to improve (Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A power analysis based on ketamine's antidepressant effects was used to determine the sample size of 18 (Murrough et al, 2013a;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which induce similar immediate antidepressant response rates (71% at 28 hours for ketamine vs. 69% at 48 hours for psilocybin) 94”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [94]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“However, ketamine’s antidepressant properties are also transient, lasting an average of 1 week following a single infusion10–14 and 18–19 days following repeated infusions.15,16”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine, an antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor (an ionotropic glutamate receptor), was shown to exhibit rapid onset and robust, short-term antidepressant effect in patients with treatment-resistant depression (TRD) [1–3].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Racemic ketamine was obtained from the Yale-New Haven Hospital Pharmacy and administered intravenously by constant infusion over 40 minutes at a dose of 0.5mg/kg, which has consistently been shown to have robust and rapid antidepressant effects 7,8 , and is typically used clinically.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Several clinical studies suggest that ketamine may also have significant anxiolytic effects.”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The cited source says what the claim attributes to it.
In the citing paper
“The results of the study are consistent with previous work suggesting that ketamine has anxiolytic effects in patients with major depression (Salvadore et al, 2009;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated the efficacy of ketamine for treatment-resistant depression (Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The cited source says what the claim attributes to it.
In the citing paper
“The lack of efficacy in our trial is likely due the fact that in our study most patients had mild to moderate depression as opposed to the more severe treatment-resistant major depression studied in ketamine clinical trials (Murrough et al, 2013a;Murrough et al, 2013b;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The cited source says what the claim attributes to it.
In the citing paper
“Intravenous ketamine administered at subanesthetic doses was found to exhibit robust and rapid onset of efficacy in patients with treatment-resistant depression (9).”
The cited source says what the claim attributes to it.
In the citing paper
“whereas it typically does not produce the sustained antidepressant response of psilocybin (35% at week 1 for ketamine vs. 71% at 1 month for psilocybin). 73,94,95”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [94]
In the citing paper
“Subsequent randomized controlled trials (RCTs) replicated this finding, demonstrating a 60–70% response rate of ketamine in TRD populations.10–14”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [11]
In the citing paper
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [73]
In the citing paper
“Comparable results have been replicated in several similarly designed RDBPCTs examining single administration of sub-anesthetic dose ketamine in patients with MDD and TRD [73,91,92,93].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [73]
In the citing paper
“Extensive experience with human patients has established that ketamine exerts rapid, robust antidepressant, antianhedonic, and antisuicidal actions within two hours of administration that are sustained for at least seven days in patients with major depression following a single infusion or intranasal administration [129-133].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [130]
In the citing paper
“Ketamine’s therapeutic effects occur within hours, with the strongest effect sizes observed at one day post-administration (Zarate et al., 2006).”
From Clinical indicators of the suicide crisis and response to ketamine (2025) · cites this paper as Zarate et al., 2006
In the citing paper
“A single, intravenous or intranasal sub-anesthetic dose of ketamine, a non-competitive NMDA glutamate receptor channel blocker, produces a rapid onset of antidepressant response that can last several days in the majority of treatment resistant unipolar and bipolar depressed patients participating in a growing number of clinical trials148–150.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [150]
In the citing paper
“Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
In the citing paper
“A subsequent double-blind randomized clinical trial demonstrated the efficacy of ketamine in treatment-resistant major depressed patients, who failed at least two conventional antidepressant treatments 5.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
In the citing paper
“The antidepressant effects of ketamine manifested within 2 hours post-infusion and 35% of patients maintained response for at least 7 days 5.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,860
A Growing Edge of Measurement of Feelings [ Abridged ]
Aitken, R. C. B. (1969) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576906201005 · Cited by 1,540
Ostwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422
Research works printed but not linked: 4
- [7]7. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobi- ology of depression. Neuron. 2002;34:13-25.
- [27]27. First MB, Spitzer RL, Gibbon M, Williams AR. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, Biometrics Research; 2001.
- [33]33. Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969;62:989-993.
- [42]42. Zarate CAJ, Singh J, Quiroz J, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. A double-blind placebo-controlled study of memantine in ma- jor depression. Am J Psychiatry. 2006;163:153-155.
Cited by
Sorted by citations
Items 901–1,000 of 1,095
Takahashi, K., Nakagawasai, O., Nemoto, W., Kadota, S., Isono, J., Odaira, T., Sakuma, W., Arai, Y., Tadano, T., & Tan–No, K. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.013 · Cited by 64
Modulation of amygdala reactivity following rapidly acting interventions for major depression
Loureiro, J. R., Leaver, A. M., Vasavada, M. M., Sahib, A. K., Kubicki, A., Joshi, S. H., Woods, R. P., Wade, B., Congdon, E. L., Espinoza, R. T., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24895 · Cited by 64
On the safety and benefits of repeated intravenous injections of ketamine for depression.
Blier, P., Zigman, D., & Blier, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.039 · Cited by 64
Effects of ketamine on cognition–emotion interaction in the brain
Scheidegger, M., Henning, A., Walter, M., Boeker, H., Weigand, A., Seifritz, E., & Grimm, S. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2015.08.070 · Cited by 64
Beyond depression: Toward a process‐based approach to research, diagnosis, and treatment.
Forgeard, M. J. C., Haigh, E. A. P., Beck, A. T., Davidson, R. J., Henn, F. A., Maier, S. F., Mayberg, H. S., & Seligman, M. E. P. (2011) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2011.01259.x · Cited by 70
Flavonoids as therapeutic candidates for emotional disorders such as anxiety and depression
Ko, Y., Kim, S., Lee, S., & Jang, C. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01292-5 · Cited by 67
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subramanian, S., Haroutounian, S., Palanca, B. J. A., & Lenze, E. J. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120152 · Cited by 73
Gupta, S. C., Yadav, R., Pavuluri, R., Morley, B. J., Stairs, D. J., & Dravid, S. M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.013 · Cited by 70
Mazzeffi, M. A., Johnson, K., & Paciullo, C. A. (2015) · Annals of Cardiac Anaesthesia · doi:10.4103/0971-9784.154478 · Cited by 64
Marsden, W. N. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.021 · Cited by 64
Ketofol in electroconvulsive therapy anesthesia: two stones for one bird
Yalçın, Ş., Aydoğan, H., Selek, S., Kucuk, A., Yüce, H. H., Karababa, F., & Bilgiç, T. (2012) · Journal of Anesthesia · doi:10.1007/s00540-012-1378-6 · Cited by 64
Optimizing Early Prediction for Antipsychotic Response in Schizophrenia
Chang, Y., Lane, H., Yang, K.-H., & Huang, C. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246211.95905.8c · Cited by 64
Meyer, J. H. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.285 · Cited by 65
NMDA antagonist treatment of depression
Williams, N., & Schatzberg, A. F. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.001 · Cited by 68
Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder
Zheng, W., Zhou, Y.-L., Liu, W.-J., Wang, C.-Y., Zhan, Y.-N., Li, H.-Q., Chen, L.-J., Li, M.-D., & Ning, Y.-P. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.005 · Cited by 64
An update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 67
Woelfer, M., Li, M., Colic, L., Liebe, T., Di, X., Biswal, B., Murrough, J., Lessmann, V., Brigadski, T., & Walter, M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1679391 · Cited by 64
Metaplastic Effects of Subanesthetic Ketamine on CA1 Hippocampal Function
Izumi, Y., & Zorumski, C. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.002 · Cited by 63
A critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
Tobacco use in bipolar disorder
Thomson, D., Berk, M., Dodd, S., Rapado-Castro, M., Quirk, S. E., Ellegaard, P. K., Berk, L., & Dean, O. M. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.1 · Cited by 63
Milak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63
Zhou, H.-Y., He, J., Hu, Z., Xue, S.-G., Xu, J., Cui, Q., Gao, S., Zhou, B., Wu, P., Long, L., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.03.967 · Cited by 63
Onaolapo, A. Y., & Onaolapo, O. J. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.297 · Cited by 72
Melatonin as a Potential Approach to Anxiety Treatment
Repova, K., Baka, T., Krajcirovicova, K., Stanko, P., Aziriova, S., Reiter, R. J., & Šimko, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416187 · Cited by 70
Lenze, E. J., Skidmore, E. R., Begley, A. E., Newcomer, J. W., Butters, M. A., & Whyte, E. M. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2813 · Cited by 63
New Therapeutic Targets for Mood Disorders
Machado‐Vieira, R., Salvadore, G., Diazgranados, N., Ibrahim, L. A., Latov, D. R., Wheeler‐Castillo, C., Baumann, J., Henter, I. D., & Zarate, C. A. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.65 · Cited by 64
Self-citationGoforth, H. W., & Holsinger, T. (2007) · Journal of Ect · doi:10.1097/01.yct.0000263257.44539.23 · Cited by 63
Lesage, A., & Steckler, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.043 · Cited by 63
The Neurobiology of Motivational Deficits in Depression—An Update on Candidate Pathomechanisms
Treadway, M. T. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_400 · Cited by 66
Papp, M., Gruca, P., Łasoń, M., & Willner, P. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000259 · Cited by 67
Ketamine as the anaesthetic for electroconvulsive therapy: The KANECT randomised controlled trial
Fernie, G., Currie, J., Perrin, J. S., Stewart, C. A., Anderson, V., Bennett, D., Hay, S., & Reid, I. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.116.189134 · Cited by 65
What Acute Stress Protocols Can Tell Us About PTSD and Stress-Related Neuropsychiatric Disorders
Musazzi, L., Tornese, P., Sala, N., & Popoli, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00758 · Cited by 68
Park, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa025 · Cited by 63
Self-citationHighland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
Self-citationAlterations of cerebral glutamate in the euthymic state of patients with bipolar disorder
Ehrlich, A., Schubert, F., Pehrs, C., & Gallinat, J. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.05.010 · Cited by 65
Gasull-Camós, J., Tarrés-Gatius, M., Artigas, F., & Castañé, A. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.7 · Cited by 64
Ren, L., & Chen, G. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.03.042 · Cited by 62
Emery, M. A., & Akil, H. (2020) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-110719-095912 · Cited by 56
Szymkowicz, S. M., Finnegan, N., & Dale, R. M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.015 · Cited by 62
Iijima, M., Fukumoto, K., & Chaki, S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.08.016 · Cited by 62
Zhu, W., Wang, S., Liu, M.-M., Shi, H., Zhang, R., Liu, J., Ding, Z., & Lü, L. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120228 · Cited by 64
Murrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62
Self-citationPrognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R. R., Zarate, C. A., & Kasper, S. F. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18205 · Cited by 64
Self-citationNitrous oxide-induced slow and delta oscillations
Pavone, K. J., Akeju, O., Sampson, A. L., Ling, K., Purdon, P. L., & Brown, E. N. (2015) · Clinical Neurophysiology · doi:10.1016/j.clinph.2015.06.001 · Cited by 61
Ketamine regulates the presynaptic release machinery in the hippocampus
Müller, H. K., Wegener, G., Liebenberg, N., Zarate, C. A., Popoli, M., & Elfving, B. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.008 · Cited by 61
Self-citationIntravenous Ketamine “Burst” for Refractory Depression in a Patient with Advanced Cancer
Stefanczyk-Sapieha, L., Oneschuk, D., & Demas, M. (2008) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.9828 · Cited by 61
Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling
Luo, Y., Yang, Y., Zhang, M., He, H., & Fan, N. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0793-6 · Cited by 62
Yao, J., Song, T., Zhang, Y., Guo, N., & Zhao, P. (2020) · Brain and Behavior · doi:10.1002/brb3.1715 · Cited by 66
Toward Synergies of Ketamine and Psychotherapy
Mathai, D. S., Mora, V., & Garcia‐Romeu, A. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.868103 · Cited by 67
New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview
Bortolozzi, A. A., Fico, G., Berk, M., Solmi, M., Fornaro, M., Quevedo, J., Zarate, C. A., Kessing, L. V., Vieta, E., & Carvalho, A. F. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000007 · Cited by 68
Self-citationMoshiri, I., Salehi, B., Mohammadbeigi, A., Kamali, A., & Taheri-nejad, M. R. (2015) · Annals of Cardiac Anaesthesia · doi:10.4103/0971-9784.166444 · Cited by 61
Emnett, C. M., Eisenman, L. N., Taylor, A. M., Izumi, Y., Zorumski, C. F., & Mennerick, S. J. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.089334 · Cited by 62
Ketamine for depression: evidence, challenges and promise
Zarate, C. A., & Niciu, M. J. (2015) · World Psychiatry · doi:10.1002/wps.20269 · Cited by 63
Self-citationLaparoscopic Surgery: A Narrative Review of Pharmacotherapy in Pain Management
Sjövall, S., Kokki, M., & Kokki, H. J. (2015) · Drugs · doi:10.1007/s40265-015-0482-y · Cited by 62
Ketofol (Mixture of Ketamine and Propofol) Administration in Electroconvulsive Therapy
Kayhan, G. E., Yücel, A., Çolak, Y. Z., Özgül, Ü., Yologlu, S., Karlidağ, R., & Ersoy, M. Ö. (2012) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1204000214 · Cited by 61
Liebe, T., Li, S., Lord, A., Čolić, L., Krause, A. L., Batra, A., Kretzschmar, M., Sweeney‐Reed, C. M., Behnisch, G., Schott, B. H., et al. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx055 · Cited by 62
Marek, G. J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_480 · Cited by 66
Strong, C. E., & Kabbaj, M. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.09.001 · Cited by 63
Comparative study of esketamine and racemic ketamine in treatment-resistant depression
Correia‐Melo, F. S., Leal, G. C.-G., Carvalho, M. S., Jesus‐Nunes, A. P., Ferreira, C. B., Vieira, F., Magnavita, G. M., Vale, L. A. S., Mello, R. P., Nakahira, C., et al. (2018) · Medicine · doi:10.1097/md.0000000000012414 · Cited by 61
Mood‐related central and peripheral clocks
Ketchesin, K. D., Becker‐Krail, D. D., & McClung, C. A. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14253 · Cited by 67
Wang, W., Liu, L., Yang, X., Gao, H. T., Tang, Q., Yin, L.-Y., Yin, X., Hao, J., Geng, D., & Gao, C. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.01.057 · Cited by 62
Rodent ketamine depression-related research: Finding patterns in a literature of variability
Polis, A. J., Fitzgerald, P. J., Hale, P. J., & Watson, B. O. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112153 · Cited by 63
Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder
McMillan, R. L., Sumner, R. L., Forsyth, A., Campbell, D. A., Malpas, G. A., Maxwell, E., Deng, C., Hay, J., Ponton, R., Sundram, F., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109838 · Cited by 66
Kokane, S. S., Armant, R. J., Bolaños‐Guzmán, C. A., & Perrotti, L. I. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112548 · Cited by 63
Iglewicz, A., Morrison, K., Nelesen, R. A., Zhan, T., Iglewicz, B., Fairman, N., Hirst, J. M., & Irwin, S. A. (2015) · Psychosomatics · doi:10.1016/j.psym.2014.05.005 · Cited by 60
Zhan, Y., Zhang, B., Zhou, Y., Zheng, W., Liu, W., Wang, C., Li, H., Chen, L., Yu, L., Walter, M., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.071 · Cited by 60
Towards translational rodent models of depression
O’Leary, O. F., & Cryan, J. F. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1587-9 · Cited by 60
Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission
Hoshaw, B. A., Hill, T. I., Crowley, J. J., Malberg, J. E., Khawaja, X., Rosenzweig-Lipson, S., Schechter, L. E., & Lucki, I. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.023 · Cited by 60
Duncan, W. C., Ballard, E. D., & Zarate, C. A. (2017) · Handbook of Experimental Pharmacology · doi:10.1007/164_2017_51 · Cited by 58
Self-citation(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression
Wang, X., Yang, J., & Hashimoto, K. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104762 · Cited by 62
Clinical pain management: Current practice and recent innovations in research
Wang, J., & Doan, L. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101786 · Cited by 74
Costa, V., Lugert, S., & Jagasia, R. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_4 · Cited by 63
Modulation of antidepressant-like activity of magnesium by serotonergic system
Poleszak, E. (2007) · Journal of neural transmission · doi:10.1007/s00702-007-0714-8 · Cited by 58
A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia
Kubota‐Sakashita, M., Iwamoto, K., Bundo, M., & Kato, T. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-5 · Cited by 60
Mendez‐David, I., Guilloux, J., Papp, M., Tritschler, L., Mocaër, E., Gardier, A. M., Bretin, S., & David, D. J. P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00462 · Cited by 63
Henderson, T. A., & Morries, L. D. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00187 · Cited by 60
Subanesthetic Ketamine Reactivates Adult Cortical Plasticity to Restore Vision from Amblyopia
Grieco, S. F., Qiao, X., Zheng, X., Liu, Y., Chen, L., Zhang, H., Yu, Z., Gavornik, J. P., Lai, C., Gandhi, S. P., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.07.008 · Cited by 60
Pasternak, J. J., & Lanier, W. L. (2009) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000048 · Cited by 61
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10l06653 · Cited by 59
Role of astrocytes in memory and psychiatric disorders
Moraga‐Amaro, R., Jerez-Baraona, J. M., Simón, F., & Stehberg, J. (2014) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2014.08.005 · Cited by 63
Short‐ and long‐term antidepressant effects of ketamine in a rat chronic unpredictable stress model
Jiang, Y., Wang, Y., Sun, X., Lian, B., Sun, H., Wang, G., Du, Z., Li, Q., & Sun, L. (2017) · Brain and Behavior · doi:10.1002/brb3.749 · Cited by 59
Ketamine Blocks Morphine-Induced Conditioned Place Preference and Anxiety-Like Behaviors in Mice
McKendrick, G., Garrett, H., Jones, H. E., McDevitt, D. S., Sharma, S., Silberman, Y., & Graziane, N. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.00075 · Cited by 58
Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization
Khoodoruth, M. A. S., Estudillo‐Guerra, M. A., Pacheco‐Barrios, K., Nyundo, A., Chapa-Koloffon, G., & Ouanes, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.886918 · Cited by 66
Bettio, L. E. B., Freitas, A. E., Neis, V. B., Santos, D. B., Ribeiro, C. M., da Rosa, P. B., Farina, M., & Rodrigues, A. L. S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.10.002 · Cited by 59
Denk, M. C., Rewerts, C., Holsboer, F., Erhardt, A., & Turck, C. W. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010128 · Cited by 59
Haj‐Mirzaian, A., Ostadhadi, S., Kordjazy, N., Dehpour, A. R., & Mehr, S. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.03.053 · Cited by 59
Trujillo, K. A., Smith, M. L., Sullivan, B., Heller, C. Y., Garcia, C., & Bates, M. L. S. (2011) · ILAR Journal · doi:10.1093/ilar.52.3.366 · Cited by 60
Catches, J. S., Xu, J., & Contractor, A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.026 · Cited by 61
Niesters, M., & Dahan, A. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.712686 · Cited by 60
Structural connectivity and response to ketamine therapy in major depression: A preliminary study
Vasavada, M. M., Leaver, A. M., Espinoza, R. T., Joshi, S. H., Njau, S. N., Woods, R. P., & Narr, K. L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.018 · Cited by 60
Molecular Neurobiology and Promising New Treatment in Depression
Jeon, S. R., & Kim, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030381 · Cited by 62
Therapeutic potential of agmatine for CNS disorders
Neis, V. B., da Rosa, P. B., Olescowicz, G., & Rodrigues, A. L. S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.05.006 · Cited by 61
Anxiolytic effects of ascorbic acid and ketamine in mice
Fraga, D. B., Olescowicz, G., Moretti, M., Siteneski, A., Tavares, M. K., Azevedo, D., Colla, A. R. D. S., & Rodrigues, A. L. S. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.02.006 · Cited by 58
Gomes, R. D. S., & Corey, E. J. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12315 · Cited by 59
Perfusion deficits, inflammation and aging precipitate depressive behaviour
Popa‐Wagner, A., Bugă, A. M., Tica, A. A., & Albu, C. V. (2014) · Biogerontology · doi:10.1007/s10522-014-9516-1 · Cited by 59
Kim, S. W., Rush, B. S., & Rice, T. (2020) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-020-01542-3 · Cited by 62
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V. D., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · NORA - Norwegian Open Research Archives · Cited by 60
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 60
mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling.
Workman, E. R., Niere, F., & Raab-Graham, K. F. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.037 · Cited by 55
Metadata
- Authors
- Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K.
- Affiliations
- National Institutes of Health (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-08-01
- Volume
- 63
- Issue
- 8
- Pages
- 856
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2109334244
- Semantic Scholar
- 3e83c317059846d97106b64a4befc4c24b87e3d1
- Cited by
- 3,766
- References
- 62
- Citations by year
- 2026: 125 · 2025: 186 · 2024: 240 · 2023: 197 · 2022: 222 · 2021: 249 · 2020: 404 · 2019: 229 · 2018: 233 · 2017: 202 · 2016: 237 · 2015: 223 · 2014: 190 · 2013: 206 · 2012: 159
- FWCI
- 48.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, NMDA receptor antagonists, treatment-resistant depression, major depressive disorder, rapid antidepressant effects, intravenous infusion, glutamatergic system, antidepressant onset of action, remission
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Cross-Over Studies, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
